Psychosis related to ropinirole [2]

American Journal of Psychiatry

Volumn 163, Issue 3, 2006, Pages 546-547

  Perea, Elena ^a   Robbins, Brian V ^a   Hutto, Burton ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DOPAMINE RECEPTOR STIMULATING AGENT; QUETIAPINE; ROPINIROLE;

ADULT; AUDITORY HALLUCINATION; CASE REPORT; DISEASE EXACERBATION; DRUG EFFECT; DRUG INDICATION; FEMALE; HUMAN; LETTER; PARANOIA; PRIORITY JOURNAL; PSYCHOSIS; RESTLESS LEGS SYNDROME; THOUGHT DISORDER; VISUAL HALLUCINATION;

EID: 33749130651     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.163.3.546     Document Type: Letter

References (4)

1. Willner P: The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997; 12(3 suppl):S7-S14
2. Singh A, Althoff R, Martineau RJ, Jacobson J: Pramipexole, ropinirole, and mania in Parkinson's disease (letter). Am J Psychiatry 2005; 162:814-815
3. Cassano P, Lattanzi L, Fava M, Navari S, Battistini G, Abelli M, Cassano GB: Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005; 50:357-360
4. Schrag AE, Brooks DJ, Brunt E, Fuell D, Korczyn A, Poewe W, Quinn NP, Rascol O, Stocchi F: The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Clin Neuropharmacol 1998; 21:169-175